We conduct extensive research into the rapidly evolving gene and cell therapy and rare diseases arena to empower clients to win. Our strategic insights identify key players and developments, tailored to support BioPharma partners across R&D, clinical, regulatory, and commercial endeavors.

The gene and cell therapy space has advanced rapidly, with new assets targeting therapeutic areas such as oncology, immunology, cardiovascular, CNS, and rare diseases. With multiple companies active and new approvals happening, it’s critical to get strategic insights, whether you are a BioPharma company or investor.

Our services include (amongst others):

For BioPharma clients:

  • Market and competitor insights on R&D, clinical development and commercial activities
  • Extensive congress coverage, supporting brand owners with up-to-date intelligence
  • Landscape analysis strengthened by expert interviews
  • BD&L support

For Investors:

  • Due diligence research
  • New opportunity identification
  • Access to experts’ opinion through a combination of in-house expertise and conduct of bespoke interviews

We also invite you to join our LinkedIn Gene, Cell and RNA Therapy Strategy Network group – a hub for networking and information.

Want to better understand and succeed in this complex space? Let’s connect!

Reach out to info@lqventures.com to learn more about our strategic consulting and research capabilities.

Respiratory Weekly News – August 8th 2025

Public Health Weekly News – August 8th 2025

Rare Diseases Weekly News – August 7th 2025

Cell and Gene Therapy Weekly News – August 7th 2025

Cardiovascular Weekly News – August 7th 2025

Immunology Weekly News – August 6th 2025

Women’s Health Weekly News – August 7th 2025

Neuroscience Weekly News – August 6th 2025

Obesity Weekly News – August 5th 2025

Endocrinology Weekly Update – August 5th 2025

Privacy Preference Center